MNOV Share Price | MediciNova, Inc. Stock Analysis & Recommendation

Q: What does MediciNova, Inc. do?

Overview: MediciNova, Inc. is a biopharmaceutical company focused on developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Net Profit: -3 Million (Quarterly Results - Mar 2025) Market cap: USD 61.80 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.73 Return on Equity: -22.35% Price to Book: 1.24Contact Details: Address: 4275 Executive Sq Ste 300, LA JOLLA CA: 92037-8408 Tel: 1 858 3731500 Fax: 1 858 4040048 Website: https://medicinova.com/

Q: Is MediciNova, Inc. overvalued or undervalued?

As of 13 November 2024, the valuation grade for MediciNova, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company is currently overvalued given its financial metrics, including a Price to Book Value of 1.39, an EV to EBIT of -2.57, and an ROCE of -94.04%. These figures suggest that the company is struggling to generate returns on its capital and is not in a favorable position relative to its peers.In comparison to its industry peers, MediciNova's valuation metrics are concerning. For instance, Talaris Therapeutics, Inc. has a P/E ratio of -5.6255 and an EV to EBITDA of -2.2059, while Ocugen, Inc. shows a P/E of -5.5401 and an EV to EBITDA of -5.6869. These comparisons highlight that MediciNova is not only underperforming but also lacks a solid foundation for growth. Additionally, the company's stock has significantly lagged behind the S&P 500, with a year-to-date return of -37.62% compared to the index's 2.44%. Overall, MediciNova, Inc. appears to be overvalued in its current state.

Q: Is MediciNova, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for MediciNova, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on a weekly basis but bearish on a monthly basis, while the KST shows a similar pattern with mild bullishness weekly and bearishness monthly. The Bollinger Bands and moving averages indicate bearish trends, particularly on the daily timeframe. Dow Theory presents a mixed view, being mildly bearish weekly and mildly bullish monthly. In terms of performance, MediciNova has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -40.95% versus the S&P 500's 12.22%, and a 1-year return of -20.00% compared to 17.14% for the index.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

79.57 k

Shareholding (Sep 2025)

FII

1.21%

Held by 13 FIIs

DII

93.73%

Held by 3 DIIs

Promoter

2.25%

How big is MediciNova, Inc.?

22-Jun-2025

As of Jun 18, MediciNova, Inc. has a market capitalization of 61.80 million and reported net sales of 0.00 million with a net profit of -11.15 million for the latest four quarters. Shareholder's funds are at 52.50 million and total assets at 55.88 million as of Dec 24.

View full answer

What does MediciNova, Inc. do?

22-Jun-2025

MediciNova, Inc. is a biopharmaceutical company developing small molecule therapeutics for serious diseases with unmet medical needs, classified as a micro-cap with a market cap of $61.80 million. As of March 2025, it reported a net profit loss of $3 million and has no dividend yield.

View full answer

Who are in the management team of MediciNova, Inc.?

22-Jun-2025

As of March 2022, the management team of MediciNova, Inc. includes Dr. Jeffrey Himawan (Independent Chairman), Dr. Yuichi Iwaki (President and CEO), Dr. Kazuko Matsuda (Chief Medical Officer), Ms. Carolyn Beaver (Director), and Mr. Hideki Nagao (Independent Director). They oversee the company's strategic direction and operations.

View full answer

Is MediciNova, Inc. overvalued or undervalued?

25-Jun-2025

As of November 13, 2024, MediciNova, Inc. is considered overvalued and has deteriorated from a risky to a non-qualifying investment grade, with poor financial metrics and a year-to-date return of -37.62%, significantly underperforming compared to its industry peers and the S&P 500.

View full answer

Is MediciNova, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, MediciNova, Inc. is in a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -40.95% versus the index's 12.22%.

View full answer

Compare MediciNova, Inc. with Similar Stocks

Abeona Therapeutics, Inc.ProQR Therapeutics NV Eton Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 83 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.74

Return on Equity

-27.32%

Price to Book

1.88

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

14.08%

6 Months

20.0%

1 Year

-16.06%

2 Years

15.3%

3 Years

-32.5%

4 Years

-31.65%

5 Years

-74.53%

MediciNova, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

2.47%

EBIT Growth (5y)

-1.68%

EBIT to Interest (avg)

-12.38

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.73

Sales to Capital Employed (avg)

0.01

Tax Ratio

0.05%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

11.33%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.39

EV to EBIT

-2.57

EV to EBITDA

-2.58

EV to Capital Employed

2.42

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-94.04%

ROE (Latest)

-22.35%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 7 Schemes (2.8%)

Foreign Institutions

Held by 13 Foreign Institutions (1.21%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -13.79% vs -3.57% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.60",
          "val2": "-3.20",
          "chgp": "-12.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.30",
          "val2": "-2.90",
          "chgp": "-13.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-26,798.80%",
          "val2": "0.00%",
          "chgp": "-2,679.88%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -27.91% vs 39.01% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "1.00",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.70",
          "val2": "-9.90",
          "chgp": "-28.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.00",
          "val2": "-8.60",
          "chgp": "-27.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-9,900.30%",
          "chgp": "990.03%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.10

0.00

Operating Profit (PBDIT) excl Other Income

-3.60

-3.20

-12.50%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-3.30

-2.90

-13.79%

Operating Profit Margin (Excl OI)

-26,798.80%

0.00%

-2,679.88%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -13.79% vs -3.57% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

1.00

-100.00%

Operating Profit (PBDIT) excl Other Income

-12.70

-9.90

-28.28%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-11.00

-8.60

-27.91%

Operating Profit Margin (Excl OI)

0.00%

-9,900.30%

990.03%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -27.91% vs 39.01% in Dec 2023

All Annual Results

Company CV

About MediciNova, Inc.

MediciNova, Inc.

Pharmaceuticals & Biotechnology

Medicinova, Inc. is a biopharmaceutical company. The company is focused on developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs. The Company is developing activities on MN-166 (ibudilast) for neurological disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction (methamphetamine dependence, opioid dependence, and alcohol dependence), and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The Company’s pipeline includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

Company Coordinates

Company Details

4275 Executive Sq Ste 300 , LA JOLLA CA : 92037-8408

Tel: 1 858 3731500

https://medicinova.com/

Registrar Details

MediciNova, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is MediciNova, Inc.?

Watch in Real-Time

What does MediciNova, Inc. do?

Who are in the management team of MediciNova, Inc.?

Is MediciNova, Inc. overvalued or undervalued?

Is MediciNova, Inc. technically bullish or bearish?

Compare MediciNova, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About MediciNova, Inc.

Company Coordinates